Aortic Valve System
TAVR Clinical Outcomes
LOTUS Valve Platform Clinical Program
LOTUS Trial Data
REPRISE III Clinical Trial
Explore the results from REPRISE III, the first head-to-head TAVR pivotal trial of the LOTUS Valve and Evolut™ R/CoreValve™ platforms. Based on the results, LOTUS showed significantly lower moderate paravalvular leak (PVL), significantly lower disabling stroke and superior procedural outcomes.
LOTUS Edge Study
See the data from the LOTUS Edge Study, which combines results from two single-arm studies with similar protocols and identical core labs designed to evaluate the safety and performance of the LOTUS Edge Aortic Valve in high-surgical-risk patients with symptomatic calcific aortic stenosis.
Explore the sub-analyses of LOTUS Valve clinical trial data, including stroke, paravalvular leak (PVL) and permanent pacemaker (PPM) rates.
Learn how our unique Adaptive Seal™ and braided valve frame conform to each patient’s anatomy, virtually eliminating paravalvular leak.
Discover how our exclusive deployment technology was designed to provide complete control, precise placement and stable deployment.